Wuhan (Novel) Corona Virus -looming pandemy of deadly pneumonia? - Pandemy ongoing!

(February 5, 2021) CureVac, UK Partner on Vaccines Against SARS-CoV-2 Variants
CureVac N.V. has entered a collaboration with the UK Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants.
Any resulting vaccine candidates will be manufactured and distributed in the UK and its overseas and territories, subject to approval.
The R&D collaboration combines CureVac’s resources and expertise in mRNA vaccine development
with the scientific experience of the Vaccines Taskforce and the UK’s network
of experts and capabilities in SARS-CoV-2 vaccine research and development.
CureVac will also transfer its technology to enable the manufacturing of clinical and commercial quantities
of any vaccines that result from the collaboration, as well as manufacturing
of CureVac's existing vaccine against SARS-CoV-2 (CVnCoV), currently in Phase 3 trials.
Subject to regulatory approval, the agreement includes an initial supply of 50 million doses
of variant vaccines to the UK with some production expected to take place in the UK.
contractpharma.com/content-microsite/covid-19/2021-02-05/curevac-uk-partner-on-vaccines-against-sars-cov-2-variants?widget=listSection

(February 5, 2021) India: Pfizer withdraws COVID vaccine application for emergency use
Pfizer Inc. said on Friday that it has pulled out an application for emergency use authorization of the BioNTech-Pfizer coronavirus vaccine in India.
The decision came after Pfizer representatives met with India’s health regulator on Wednesday,
who refused to grant the pharmaceutical's vaccine the authorization, citing a lack of immunogenicity trials.
The company said that it would shortly submit another authorization request with further information when available.
India's drug regulator wanted Pfizer to conduct local trials to ensure the safety of the vaccine for official authorization.
But the company failed to present evidence that its vaccine was safe for the Indian population,
according to a Central Drugs Standard Control Organization (CDSCO) statement.
dw.com/en/india-pfizer-withdraws-covid-vaccine-application-for-emergency-use/a-56462616

(February 5, 2021) Novavax inks agreement with Switzerland government to supply six million doses of protein-based Covid-19 vaccine candidate, NVX-CoV2373
Novavax announced that the company has executed a binding Heads of Terms agreement with the government of Switzerland
to supply six million doses of its protein-based Covid-19 vaccine candidate, NVX-CoV2373, to the country.
Novavax and Switzerland will negotiate a final agreement, with initial delivery of vaccine doses slated to ship
following successful clinical development and regulatory review. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology
to generate antigen derived from the coronavirus spike (S) protein and is adjuvanted with Novavax’ patented saponin-based Matrix-M
to enhance the immune response and stimulate high levels of neutralizing antibodies.
pharmabiz.com/NewsDetails.aspx?aid=135319&sid=2

(February 5, 2021) UK government orders another 40 million doses of Valneva’s vaccine candidate
The UK Government has ordered 40 million more doses of Valneva’s adjuvanted COVID-19 vaccine candidate for supply in 2022.
This increases the total doses of the Valneva vaccine ordered by the UK Government to 100 million.
Plus, the UK Government retains options for possibly a further 90 million doses for supply between 2023 and 2025.
If all options are exercised, the total value of the 190 million doses is 1.4 billion euros.
Valneva is in advanced discussions with the European Commission regarding the supply of up to 60 million doses.
homelandprepnews.com/stories/62731-uk-government-orders-another-40-million-doses-of-valnevas-vaccine-candidate/

(February 4, 2021) Singapore approves interim authorization of Moderna COVID-19 vaccine
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,
has announced that the Singapore Health Sciences Authority (HSA) has approved the interim authorization
of its mRNA vaccine against COVID-19 (COVID-19 Vaccine Moderna) for use under the Pandemic Special Access Route (PSAR).
The Singapore Ministry of Health has secured access to COVID-19 Vaccine Moderna through a supply agreement announced on December 14, 2020.
Moderna has also received authorization for its COVID-19 vaccine from health agencies
in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland.
biospectrumasia.com/news/37/17547/singapore-approves-interim-authorization-of-moderna-covid-19-vaccine.html

(February 5, 2021) Australia secures total of 20 million Pfizer-BioNTech vaccines
The Australian Government has secured an additional 10 million doses of the Pfizer-BioNTech COVID 19 vaccine
on the advice of the Scientific Industry Technical Advisory Group on Vaccines.
Through the Government’s Advance Purchase Agreement with Pfizer, this additional 10 million vaccines
means Australia will now receive 20 million Pfizer doses in 2021.
biospectrumasia.com/news/37/17557/australia-secures-total-of-20-million-pfizer-biontech-vaccines.html

(February 5, 2021) Pentagon will deploy troops to assist COVID-19 vaccine drive
WASHINGTON — The Pentagon will deploy troops to assist getting Americans vaccinated
against COVID-19, the White House said Friday. Coronavirus senior adviser Andy Slavitt announced
that Defence Secretary Lloyd Austin has approved a request for assistance from the Federal Emergency Management Agency.
It means about 1,000 active duty military personnel will deploy to help state vaccination centres.
rdnewsnow.com/2021/02/05/pentagon-will-deploy-troops-to-assist-covid-19-vaccine-drive/

(February 5, 2021) UK discussing coronavirus immunity passport options for travel
UK ministers are looking into the creation of a digital vaccine passport, government sources have confirmed, Sky News reports.
Research groups are said to have been set up on the subject as attention
turns to what will happen to international travel once jabs are more widely rolled out across the world.

Foreign Office minister James Cleverly earlier avoided confirming the news,
only telling Sky News that countries will "set their own border measures" – as well as defending the delay to hotel quarantine plans.
But The Times reported on Friday that a certification system is being planned by three government departments
to let travellers go abroad to countries that may demand proof of inoculation.

It also said Greece is preparing to waive quarantine rules for those who have been vaccinated.
Sweden's government announced on Thursday it plans to launch a digital coronavirus vaccine passport by summer,
if there is an international standard in place by then. And Denmark also said this week it would launch a first version of the document by the end of February.

Tony Blair is one of those who has been pushing for the UK government to take a lead on the issue,
suggesting last week the UK should take advantage of chairing the G7 and push for other countries to develop the documents.
Turning his attention to what happens next, Blair's institute said the UK should "place the creation of a global coronavirus travel pass
as a key item on the G7 agenda,'' when leaders from the US, France, Germany, Italy, Japan and Canada congregate in Cornwall later this summer.
thestandard.com.hk/breaking-news-print/165069/UK-discussing-coronavirus-immunity-passport-options-for-travel

(February 6, 2021) Daiichi Sankyo enters outsourcing agreement to manufacture AstraZeneca-developed Covid-19 vaccine, AZD1222, in Japan
Daiichi Sankyo Company announced that it recently entered into an outsourcing agreement
with AstraZeneca K.K. to manufacture the AstraZeneca-developed covid-19 vaccine, AZD1222, in Japan.
In order to play a part in the Covid-19 vaccine manufacturing and supply scheme
agreed upon between AstraZeneca and the government of Japan,
Daiichi Sankyo will use undiluted solutions provided by AstraZeneca
to manufacture Covid-19 vaccines in the country, including vial filling and packaging, in accordance with the outsourcing agreement.
pharmabiz.com/NewsDetails.aspx?aid=135335&sid=2

(February 6, 2021) COVID-19 Vaccination is Voluntary for Military Personnel
The US Department of Defense (DOD) announced on February 5, 2021, Army Gen. Mark A. Milley,
chairman of the Joint Chiefs of Staff, and his wife Hollyanne said they are committed
to protecting the military's 2.3 million men and women and 2.7 family members from COVID-19.
The DOD reported there have been about 145,000 coronavirus cases amongst Active Duty personnel and 21 fatalities (0.014%)
related to COVID-19 during the pandemic. Gen. Milley noted that the National Institutes of Health (NIH)
and the Food and Drug Administration (FDA) have declared the vaccines as "safe and highly effective" but
he acknowledged that getting the vaccine is a personal decision.
precisionvaccinations.com/vaccine-breaking-news

(February 7, 2021) Hundreds protest Covid restrictions in Denmark
Hundreds of people took to the streets of Copenhagen on Saturday night to protest
Denmark's Covid-19 restrictions and the country's plans for a digital vaccination certificate.
Organised by a group calling itself "Men in Black," some 600 people gathered in the bitter cold
in front of the parliament building to protest the "dictatorship" of Denmark's partial lockdown.
Plans for a digital vaccine "passport" were a main target of their anger.
Protest organisers say such a passport implies an obligation to be vaccinated
and amounts to a further restriction on individual freedom. Vaccination is not compulsory in Denmark.
thelocal.dk/20210207/hundreds-protest-covid-restrictions-in-denmark

Abacus wrote:(February 7, 2021) Hundreds protest Covid restrictions in Denmark
Hundreds of people took to the streets of Copenhagen on Saturday night to protest
Denmark's Covid-19 restrictions and the country's plans for a digital vaccination certificate.
Organised by a group calling itself "Men in Black," some 600 people gathered in the bitter cold
in front of the parliament building to protest the "dictatorship" of Denmark's partial lockdown.
Plans for a digital vaccine "passport" were a main target of their anger.
Protest organisers say such a passport implies an obligation to be vaccinated
and amounts to a further restriction on individual freedom. Vaccination is not compulsory in Denmark.
thelocal.dk/20210207/hundreds-protest-covid-restrictions-in-denmark

Abacus check out Vernon Coleman in the UK lots of good info there

Abacus check out Vernon Coleman in the UK lots of good info there

Hi khnum,
there seems to be vast amount of webpages about Vernon Coleman
can you please share some link.
Thank you

Abacus wrote:

Abacus check out Vernon Coleman in the UK lots of good info there

Hi khnum,
there seems to be vast amount of webpages about Vernon Coleman  
can you please share some link.
Thank you

I don't know how to link here but vernancoleman.com/main.htm will find him

Ok thx Khnum,
it seems this one is the right link: vernoncoleman.com/hnat.htm

(January 24, 2021) 17-year-old in ICU after receiving second coronavirus vaccine dose
A 17-year-old was hospitalized in the Safra Children’s Hospital's ICU at Sheba Medical Center
a few days after receiving the second dose of the coronavirus vaccine, according to the hospital.
The youth arrived at the hospital after feeling intense pains in his chest. He does not have any preexisting conditions.
A doctor from the department said that the boy is in stable condition and that the hospital does not believe that his symptoms are connected to the vaccination.
jpost.com/breaking-news/17-year-old-in-icu-after-receiving-second-coronavirus-dose-656527

(February 1, 2021) 19-year-old hospitalized in ICU days after receiving second Pfizer vaccine
A 19-year-old was hospitalized with myocarditis – inflammation of the heart muscle – five days after receiving his second dose of the coronavirus vaccine,
Terem emergency medical clinic reported Monday. According to the clinic, it has still not been confirmed that the inflammation was developed as a side effect of the vaccination.
However, a number of COVID-19-related myocarditis cases have been reported,
according to the US National Institutes of Health.
jpost.com/health-science/19-year-old-hospitalized-with-heart-inflammation-after-pfizer-vaccination-657428

(February 7, 2021) Ministry of the Interior hired scientists to justify corona measures
An extensive correspondence that WELT AM SONNTAG has available shows: In the first high phase of the pandemic,
Interior Minister Horst Seehofer's house acted on researchers. Thereupon they provided results for a dramatic "secret paper" of the ministry.
Interior Ministry stressed in the first wave of the pandemic Corona in March 2020 scientists from several research institutes and universities for political purposes.
It commissioned the researchers from the Robert Koch Institute and other institutions to create a calculation model
on the basis of which the Ministry of the Interior, Horst Seehofer (CSU), wanted to justify tough corona measures.
This emerges from more than 200 pages of internal correspondence between the management level of the Ministry of the Interior
and the researchers that WELT AM SONNTAG has received. A group of lawyers fought for e-mail in a legal dispute with the Robert Koch Institute that lasted several months.
welt.de/politik/deutschland/article225864597/Interner-E-Mail-Verkehr-Innenministerium-spannte-Wissenschaftler-ein.html?fbclid=IwAR0qcmt_a5w4AXf6KZe0Ey3Sv66WVsga8UsmJKCyxGtaxqAGLk0aIF6DYyM

(February 8, 2021) EU orders 300 million more BioNTech-Pfizer vaccine doses
The European Commission has wrapped up a deal to receive another 300 million doses of the BioNTech-Pfizer coronavirus vaccine,
a spokesperson told several news agencies Monday. The EU reached a deal with Pfizer in November for 300 million doses
and in January negotiated a preliminary deal for another 300 million.
An EU official told Reuters that the bloc would receive 200 million doses of the vaccine in 2021.
The timeline for the other 100 million was still unclear.
dw.com/en/eu-orders-300-million-more-biontech-pfizer-vaccine-doses/a-56502706

(February 8, 2021) FEMA Launches COVID-19 Super Vaccination Sites
Texas Governor Greg Abbott announced via Twitter on February 8, 2021,
'Texas is working with FEMA to create Super Sites for COVID-19 vaccinations.
Initially, there would likely be 2 sites with up to 6,000 additional vaccinations per day,
7 days a week for 8 weeks. The FEMA program would likely start (vaccinations) in Houston & Dallas,
with possible expansion to other locations.'
precisionvaccinations.com/vaccine-breaking-news

(February 9, 2021) SA turns to J&J vaccine to begin COVID-19 immunisation programme
CAPE TOWN - South Africa has shifted gears and is now hinging its hopes on the single-dose Johnson & Johnson COVID-19 vaccine.
During a World Health Organization (WHO) briefing on Monday, the chairperson of government’s Ministerial Advisory Committee on COVID-19,
Professor Salim Abdool Karim, said that they were scheduled to roll out the AstraZeneca vaccine in just over a week from now.
"Instead of rolling out the AstraZeneca vaccine, we'll be rolling out the Johnson & Johnson vaccine
and that will give us a bit of time and leeway to ensure that we're collecting the necessary data
as we roll out the AstraZeneca in a stepwise process."
ewn.co.za/2021/02/09/sa-turns-to-j-and-j-vaccine-to-begin-covid-19-immunisation-programme

(February 10, 2021) ICC, Mastercard, IBM join ID2020 Good Health Pass initiative
Yesterday ID2020 launched the Good Health Pass Collaborative to encourage interoperability
between the COVID-19 health credentialing solutions being developed by numerous organizations.
Members of the new initiative include the Airports Council International (ACI), Hyperledger,
COVID-19 Credentials Initiative, International Chamber of Commerce (ICC),
Mastercard and numerous others (full list below).
“Fragmentation is a risk we simply cannot ignore,” said ID2020 Executive Director Dakota Gruener.
“To be valuable to users, credentials need to be accepted at check-in,
upon arrival by border control agencies, and more.”
“We can get there — even with multiple systems — as long as solutions adhere
to open standards and participate in a common governance framework.

Good Health Pass Collaborative members: Affinidi, Airport Council International (ACI), Airside, analizA, (ICC) AOKpass,
Bindle Systems, BLOK Solutions, CLEAR, The Commons Project Foundation, Covid Credential Initiative (CCI), Daon, Everynym,
Global Privacy & Security by Design Centre, Grameen Foundation, Hyperledger, IBM, idRamp, International Chamber of Commerce (ICC), iProov,
Linux Foundation Public Health, Lumedic, Mastercard, MIT SafePaths, National Aviation Services (NAS),
Panta, PathCheck Foundation, Prescryptive Health, SITA, STChealth, Trust Over IP Foundation, ZAKA.
ledgerinsights.com/icc-mastercard-ibm-join-id2020-good-health-pass-vaccine-credentials/

(February 10, 2021) AstraZeneca Plans Higher Covid Vaccine Output For EU
AstraZeneca plans to accelerate production of its Covid vaccine in the second quarter
to support EU needs, the British pharmaceutical giant said Wednesday, announcing a deal with Germany's IDT Biologika.
Beyond the immediate need for more vaccines, the agreement will see both companies invest to increase capacity
at a production site in Dessau, eastern Germany, to produce millions of doses monthly by the end of 2022.
Last week meanwhile saw a separate Anglo-German collaboration announced, with Britain's GlaxoSmithKline and Germany's CureVac
teaming up to develop a vaccine that can potentially counter multiple variants of Covid-19.
barrons.com/news/astrazeneca-says-to-boost-vaccine-manufacturing-for-europe-with-germany-s-idt-biologika-01612968306?tesla=y

Le Cercle (formerly the Pinay Group)
is a deep state milieu of a comparable age to the Bilderberg, but smaller, spookier, more secretive and less exposed.
David Teacher wrote that the group “can be seen to be an international coalition of right-wing intelligence veterans, propaganda assets
and top politicians who would shape the 1970s and 1980s.” It was entirely European for 15 years, but since 1968 it has met annually in both Washington DC and Europe.
Although the group bore the name of Antoine Pinay (French Prime minister in 1952) it is believed to have been organised by Jean Violet,
a close associate of his since 1951.

It arose from a Franco-German alliance (possibly in connection with Operation Gladio)
and originally its anti-communism had a catholic Christian flavour.
The group currently meets biannually, in Washington DC every Autumn and in Spring across the Atlantic,
usually in Europe, although David Rockefeller's autobiography states that it used to meet "thrice yearly".
Many important members tend to be affiliated with the aristocratic circles in London or obscure elements within the Vatican,
and accusations of links to fascism and synarchism are anything but uncommon in this milieu.
Two former chairmen of Le Cercle, Kwasi Kwarteng and Nadhim Zahawi
"denied they had any knowledge of how Le Cercle funds its operations."

The significant presence of Paneuropa-affiliated Opus Dei members and Knights of Malta,
together with statements of the Vatican and Otto von Habsburg,
suggest an agenda of creating a new "Holy Roman Empire" with borders from the Atlantic
to the Black Sea and from the Baltic Sea to North Africa.
Interestingly, the latest generation of British Cercle members,
whose predecessors were keen on joining the European Union, now seem to want to keep Britain out of the emerging European superstate,
perhaps having lost faith they can become a significant force within Europe. Their American associates, however, would like for them to continue the effort
of breaking into the Franco-German alliance and possibly to establish a new Anglo-German alliance.
wikispooks.com/wiki/Le_Cercle#cite_note-22


(August 16, 2018) Pfizer pays BioNTech $120M upfront to form mRNA flu vaccine pact

(March 17, 2020) Pfizer, BioNTech strike COVID-19 deal, commit multiple R&D sites to vaccine development

(July 3, 2020) Tesla filed joint patent with CureVac on possibly revolutionary ‘bioreactor for RNA’[/b]

(November 29, 2020) Coronavirus inoculations in UK to be overseen by vaccines minister MP Nadhim Zahawi(ex Le Cercle)

(February 3, 2021) GSK, CureVac partnership eyes Covid-19 vaccine against multiple variants

(February 5, 2021) CureVac, UK Partner on Vaccines Against SARS-CoV-2 Variants

(February 10, 2021) Astrazeneca announcing a deal with Germany's IDT Biologika

(February 8, 2021) Verily links with Janssen for at-home COVID-19 immune system study
Verily is teaming up with Johnson & Johnson’s Janssen division to observe
the body’s earliest immune responses to a coronavirus infection,
with people participating in the research from within their own homes.
The study will be launched through Verily’s Project Baseline testing program and aims to collect biological information
and real-world data in the weeks immediately after a person tests positive for COVID-19.
Separately, Verily recently opened up its coronavirus-focused Project Baseline efforts to children as young as four,
while pediatric testing and COVID-19 research has previously been limited.
The program will offer free COVID-19 testing to children through 450 screening sites across 16 states.
fiercebiotech.com/medtech/verily-links-janssen-for-at-home-covid-immune-system-study

(February 11, 2021) USA Purchases Another 100 Million COVID-19 Vaccine Doses
Massachusetts-based Moderna, Inc. announced on February 11, 2021, the U.S. government has purchased an additional 100 million doses
of Moderna’s COVID-19 Vaccine, bringing its confirmed order commitment to 300 million doses.
Moderna has supplied 41 million released doses of the vaccine to the U.S. government to date.
Moderna is working with its domestic manufacturing partners and the U.S. FDA to continue to explore ways to accelerate delivery,
to provide this new order of 100 million doses before the end of July 2021.
precisionvaccinations.com/vaccine-breaking-news

(February 12, 2021) Evonik Strengthens Partnership with BioNTech on COVID-19 Vaccine
Evonik is investing in the short-term expansion of its specialty lipids production
which are essential for mRNA-based COVID-19 vaccines.
Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany
as early as the second half of 2021 as part of a strategic partnership with vaccine manufacturer BioNTech.
This step contributes to increasing the supply security of the Pfizer-BioNTech COVID-19 vaccine.
contractpharma.com/content-microsite/covid-19/2021-02-12/evonik-strengthens-partnership-with-biontech-on-covid-19-vaccine?widget=listSection

(February 12, 2021) Pfizer, BioNTech to Supply the U.S. with 100mn Additional Doses of COVID-19 Vaccine
Pfizer and BioNTech SE said that the U.S. government has exercised its option for an additional 100 million doses
of the Pfizer-BioNTech COVID-19 vaccine. This brings the total number of doses to be supplied by the companies to the U.S. government to 300 million.
Consistent with the agreements for the prior 200 million doses, the U.S. government will pay $1.95 billion for the additional 100 million doses.
Pfizer’s facility in Kalamazoo, MI, remains the primary manufacturing site of the Pfizer-BioNTech COVID-19 vaccine in the U.S.
contractpharma.com/content-microsite/covid-19/2021-02-12/pfizer-biontech-to-supply-the-us-with-100mn-additional-doses-of-covid-19-vaccine?widget=listSection

(February 10, 2021) SARS-CoV-2 Infection Prevented and Treated in Human Lung Tissue Model
Now, scientists at UNC have found that the orally administered experimental drug EIDD-2801 (now known as molnupiravir or MK-4482)
halts SARS-CoV-2 replication and prevents infection of human cells in a new in vivo lab model containing human lung tissue.
Separate Phase II and III clinical trials are ongoing to evaluate molnupiravir safety in humans
and its effect on viral shedding in COVID-19 patients, and the first results could be released as early as March.
This work is published in Nature in the paper titled, “SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.”
Molnupiravir is being developed by Merck & Co. in collaboration with Ridgeback Therapeutics.

Mouse models can be useful in studying highly pathogenic human coronaviruses including SARS-CoV-2 and compounds that might control infection.
But human coronaviruses do not replicate in mice unless researchers alter the virus,
genetically modify the mice, or introduce the individual human receptor genes into mice so the virus can infect cells.
Such mouse models have added to the scientific community’s understanding of coronavirus infection and disease progression,
but none of these models possess the diverse human cells found in human lungs where viral infection can cause severe disease.

UNC scientists created a solution to this problem—a line of mice with human lung tissue
that includes all the primary human cells infected when individuals fall ill with COVID-19.
In this study, they used a single experimental platform based on human lung-only mice (LoM)
to demonstrate efficient in vivo replication of all recently emerged human coronaviruses
(SARS-CoV, MERS-CoV, and SARS-CoV-2) and two highly relevant endogenous pre-pandemic SARS-like bat coronaviruses.
genengnews.com/news/sars-cov-2-infection-prevented-and-treated-in-human-lung-tissue-model/

(February 13, 2021) Qatar Health Ministry grants Emergency Use Authorization for Moderna’s Covid-19 vaccine
Moderna announced that the Qatar Ministry of Public Health has issued an emergency use authorization for Covid-19 Vaccine Moderna.
Qatar has secured access to Covid-19 vaccine Moderna through a supply agreement announced on October 26, 2020.
Moderna has also received authorization for its Covid-19 vaccine from health agencies in the United States, Canada, Israel, the European Union, the United Kingdom, Switzerland and Singapore.
Moderna is also working with additional health agencies and with the World Health Organization on the authorization of its vaccine in respective jurisdictions.
pharmabiz.com/NewsDetails.aspx?aid=135487&sid=2

(February 13, 2021) FUJIFILM Diosynth Biotechnologies Welcomes UK Prime Minister Boris Johnson to UK COVID-19 Vaccine Manufacturing Site
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and viral vectors,
welcomed UK Prime Minister Boris Johnson to Teesside at its Billingham site,
on Saturday 13 February to meet the team working to support the manufacture of a COVID-19 vaccine candidate.
During the visit, the Prime Minister toured the FUJIFILM Diosynth Biotechnologies facilities
where the antigen component (active ingredient) of Novavax' NVX-CoV2373 COVID-19 vaccine
will be manufactured as well as other life-impacting therapies.
Fujifilm's leading technical expertise in baculovirus systems and biopharmaceutical manufacturing
excellence is contracted by Novavax to produce antigen for up to 180 million vaccine doses.
bionj.org/news/pr-newswire-global?rkey=20210213EN79439&filter=16221

(February 13, 2021) Oxford AstraZeneca Covid vaccine could give kids ‘life long immunity’ as trials on children as young as five loom
Pfizer is starting a trial for children aged five to 11 while Oxford AstraZeneca is doing this with kids as young as six to 17.
Scientists will use volunteers to assess whether the jab will produce a strong immune response in kids.
The Oxford jab is one of three to have been approved for use in adults in the UK, along with those from Pfizer/BioNTech and Moderna.
Professor Sarah Gilbert, chief investigator on the Oxford team that developed the AstraZeneca vaccine, told The Times: "We’re all really waiting to see how things play out.
thesun.co.uk/news/14038402/oxford-astrazeneca-covid-vaccine-give-kids-life-long-immunity/

(February 15, 2021) WHO approves AstraZeneca/Oxford Covid-19 vaccine for emergency use
GENEVA — The World Health Organization on Monday listed AstraZeneca and Oxford University's Covid-19 vaccine for emergency use,
widening access to the relatively inexpensive shot in the developing world.
A WHO statement said it had approved the vaccine as produced by AstraZeneca- SKBio (Republic of Korea) and the Serum Institute of India.
The COVAX Facility, which is co-led by the vaccine alliance Gavi, the World Health Organization, the Coalition for Epidemic Preparedness Innovations(CEPI)
and the U.N. Children’s Fund, has said doses would cover an average of 3.3 percent of total populations of 145 participating countries.
nbcnews.com/news/world/who-approves-astrazeneca-oxford-covid-19-vaccine-emergency-use-n1257949

Indoctrination cartoon:
What if Bill Gates Disappeared?
youtube.com/watch?v=5nsIE94PYac

(January 29, 2021) How Influencers, Celebrities, and FOMO(Fear of missing out) Can Win Over Vaccine Skeptics

Inspire FOMO. Second, we recommend incentivizing the fear of missing out, both socially and economically.
For example, recently 82 percent of adults said they are not comfortable visiting family or close friends
inside their homes during the COVID-19 pandemic. This inability to socialize is more likely to influence
late majority and laggard groups to take the vaccine than health-related messages.

Since multiple vaccines and data on vaccines may be available by the time the late majority and laggards are ready
to make a decision, it is important that trusted sources inform this segment, so that they feel they are educated
and making the correct choice. For example, in 2016, US health authorities successfully used such a strategy during the Zika virus scare
to pinpoint the late majority and laggard segments of vulnerable populations
based on their demographics, behavior, and interests, allowing them to target their messages.
hbswk.hbs.edu/item/how-influencers-celebrities-and-fomo-can-win-over-vaccine-skeptics

The World Economic Forum linked this article here:
intelligence.weforum.org/topics/a1G0X000006O6EHUA0?tab=publications

(February 17, 2021) Pfizer, BioNTech To Supply 200M More Vax Doses to EU
Pfizer Inc. and BioNTech SE have entered an agreement with the European Commission (EC) to supply an additional 200 million doses of COMIRNATY,
the companies’ COVID-19 vaccine, to the 27 European Union (EU) member states. The EC has the option to request supply of an additional 100 million doses.
This new agreement is in addition to the 300 million doses that have already been committed to the EU through 2021 under the first supply agreement signed last year.
The additional 200 million doses are expected to be delivered in 2021, with an estimated 75 million to be supplied in the second quarter.
The total number of doses to be delivered to the EU member states by the end of 2021 is now 500 million,
with the potential to increase to 600 million based on the option granted in the new agreement.
contractpharma.com/content-microsite/covid-19/2021-02-17/pfizer-biontech-to-supply-200m-more-vax-doses-to-eu?widget=listSection

(February 17, 2021) Novavax, SK Bioscience expand Covid-19 vaccine manufacturing deal
Novavax and SK Group’s vaccine business subsidiary, SK Bioscience, have expanded collaboration
and license agreement for manufacturing and commercialisation
of the former’s Covid-19 vaccine, NVX-CoV2373, for sale to the Korean government.
With the agreement expansion, SK Bioscience will also increase production capacity.
The latest development is in addition to an already existing manufacturing arrangement between the companies
for developing and supplying the protein antigen component of NVX-CoV2373 to be supplied to global markets such as the COVAX Facility.
This agreement calls for technology transfer linked to Novavax’s protein antigen manufacturing, Matrix M
adjuvant supply and extending support to SK Bioscience to obtain regulatory approval.
pharmaceutical-technology.com/news/novavax-sk-bioscience-deal/

(February 17, 2021) Novartis, Gates Foundation ally on in vivo sickle cell gene therapy
Novartis is adding sickle cell disease to its gene therapy stable through a partnership with the Bill & Melinda Gates Foundation.
The latter will support a research team at the Swiss Pharma dedicated to discovering and developing a one-and-done
in vivo treatment that can be given easily to patients all over the world.
Caused by a single mutation in the gene that codes for beta-globin, a component of red blood cells, sickle cell
is a well-known genetic disorder that disproportionately affects people of African descent.
Novartis aims to develop a gene therapy that works inside the body,
which could be given to the patient without the need to extract their cells,
modify them in a laboratory and then put them back into the patient.

The partnership comes one day after bluebird bio suspended two clinical trials of its ex vivo sickle cell gene therapy because two patients developed blood cancer.
While the trials are on hold, the company will investigate whether the lentiviral vector used in the gene therapy is linked to the cases of acute myeloid leukemia and myelodysplastic syndromes.
fiercebiotech.com/biotech/novartis-gates-foundation-ally-vivo-sickle-cell-gene-therapy

(February 18, 2021) Vatican employees could lose their jobs for refusing COVID vaccine
The Vatican has taken a hard line against employees who refuse to be vaccinated for COVID-19, warning they risk losing their jobs.
According to a decree by Cardinal Giuseppe Bertello, whose role as President of the Pontifical Commission for Vatican City State
makes him the territory's top administrator, employees who refuse the vaccine "without proven health reasons" face penalties
that can include "the interruption of the work relationship."
cbsnews.com/news/vatican-covid-vaccine-mandatory-employees/